Healthcare industry is one of the biggest industries in Australia and investors should always keep a close eye on the stocks that are part of this Industry. The below mentioned two Healthcare Stocks have made some key strategic progress in the recent past. Let’s take a closer look at these stocks –
Biotron Limited (ASX: BIT)
Biotron Limited (ASX: BIT) is a publicly listed Australian Biotechnology Company which is involved in the development for the treatment of HIV-1 and Hepatitis C virus infections, and it also has a robust preclinical pipeline which includes an impressive portfolio of compounds with activity against a broad range of viral diseases. Earlier in December 2018, the company raised around $4.7 million by exercising around 77.12 million options, placing the company in a decent financial position. The proceeds raised from the exercise of options will allow Biotron to advance the development of other promising compounds. In late September 2018, the company announced positive headline data from its pivotal Phase 2 clinical trial for the treatment of HIV?1. After receiving positive results from the clinical trial, the company is progressing the HIV?1 program towards a commercial outcome. Further, the company is also evaluating the activity of Biotron compounds for activity against Hepatitis B virus (HBV). With the positive data from the Phase 2 HIV?1 clinical trial in hand and a sound financial position resulting from this significant injection of funds, the Company ended 2018 in a robust position.
In last one year, the company’s shares increased substantially by 414.46 percent as on 10 January 2019. BIT’s shares last traded at $0.135 (down 3.6%) with a market capitalization of circa $83.29 million as on 11 January 2019.
Bionomics Limited (ASX: BNO)
Clinical stage biopharmaceutical company, Bionomics Limited (ASX: BNO) is involved in the research and development of treatment of diseases like cancer, depression and Alzheimer’s disease.
Earlier in December 2018, the company received A$654k in licensing revenue from its participation in the Cancer Therapeutics CRC. In December 2018, the company raised $250,000 through a Share Purchase Plan (SPP) and received A$6,568,808 R&D Tax Incentive Refund for the 2017/2018 financial year. Following which in January 2019, Bionomics initiated its phase II clinical trial of its cancer drug candidate, BNC105, in combination with Bristol-Myers Squibb’s nivolumab to investigate whether BNC105 can be used for the treatment of advanced colorectal cancer patients.
The company is transitioning into a focused Central Nervous System (CNS) disorders company. Further, the company is progressing its plan to monetize its oncology programs through divestments. In the financial year 2018, Bionomics Limited earned a revenue of $3.95mn which was 79% less than the revenue of FY 2017. The loss after tax of the company increased from $6.75M in FY 2017 to $25.08M in FY 2018. In September quarter of 2018, the company reported Cash receipts of $2.19 million. As at 30 September 2018, the company had a cash balance of $16.67M. In the last one year, the share price of the company decreased by 66.23 percent as on 10 January 2019. BNO’s shares traded at $0.125 (down 3.8%) with a market capitalization of circa $70.81 million as on 11 January 2019.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.